Showing 112 of 112on this page. Filters & sort apply to loaded results; URL updates for sharing.112 of 112 on this page
Kailera Therapeutics Announces First Participants
Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats ...
Kailera Therapeutics Completes $718.8 Million Nasdaq IPO
Kailera Therapeutics Inc. – Filings and Transcripts – BamSEC
Kailera Therapeutics IPO — Price Range, Offering Size, Listing Date 2026
Kailera Therapeutics Files for US Initial Public Offering | IUX24
Kailera Therapeutics | GLP-1 Therapies for Obesity Care
Kailera Therapeutics Announces Pricing of Initial Public Offering ...
Kailera breaks biotech IPO record with $625M debut - PharmaLive
Kailera nets $625M in one of biotech’s biggest-ever IPOs | BioPharma Dive
Kailera sets IPO record with Nasdaq listing set to raise at least USD ...
Kailera plans $528.5 million IPO to support obesity assets
Kailera Therapeutics files for US IPO to fund obesity drugs
Kailera Therapeutics Raises $718.8 Million in Initial Public Offering
Evercore ISI Group Initiates Coverage On Kailera Therapeutics with ...
Kailera nets $600m to power Phase III launch of obesity drug
Kailera sets $16 IPO price, raising $625m for obesity care
Kailera Therapeutics IPO: GLP-1 Obesity Pipeline Analysis | IntuitionLabs
ADA: Kailera ‘back at work’ after record-breaking IPO with China data ...
Kailera Therapeutics Reports Q1 2026 Financial Results, Advances ...
Kailera Q1 2026 loss widens as obesity trials ramp | KLRA 8-K Filing
Kailera Therapeutics Launches with $400 Mn Series A Funding
Kailera | GLP-1 Therapy for Obesity | Ribupatide
Kailera | GLP-1 Therapies for Obesity Management | Contact
Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy
Kailera Therapeutics | GLP-1 Therapies for Clinical Obesity
Kailera Therapeutics - 22 Fillmore
A new benchmark for biotech IPOs? Kailera raises $625M
Kailera Therapeutics Appoints Jamie Coleman as Chief Commercial Officer ...
Kailera | GLP-1 Therapies for Obesity Care | Open Positions
Kailera | GLP-1 Therapies for Weight Control | Leadership
Kailera Files for IPO as Biotech Sector Sees FDA Wins, Insider Buying
Kailera Therapeutics: KLRA IPO, Health Care - Phase 3 biotech ...
Investors Back Kailera with $1 Billion Amid IPO Hopes | PipelineRoad
Kailera Therapeutics Launches with Ambitious Plans for GLP-1 Drugs ...
Kailera | GLP-1 Therapies for Obesity Care | Drug Pipeline
Kailera Therapeutics Announces $600 Million Series B | citybiz
UPDATE: Kailera breaks biotech IPO record with $625M debut - BioSpace
Kailera Therapeutics Stock | Valuation, Funding, Investors | Notice.co
#kainections #kaicrew #kaileratx | Kailera Therapeutics
Kailera | GLP-1 Therapies for Obesity Care | Clnical Trials
Kailera Therapeutics 6.25億美元IPO首日飆漲逾60%，引爆減肥藥投資熱潮 — BigGo 財經
Kailera IPO interview: CEO Renaud talks biotech market, China and ...
Kailera Breaks the Biotech IPO Record at $625M • Foundayo Logs 1,390 ...
Kailera Therapeutics Launches with $400 Million Series A Financing to ...
Kailera sets biotech IPO record with $625 million raise
Kailera Therapeutics | Events & Presentations
Kailera Launches With $400M to Advance China-Developed Obesity Assets ...
Kailera Therapeutics emerges from stealth with $400M for obesity drugs ...
Kailera plots IPO to fuel obesity pipeline
#kaicrew #kainections #kaileratx #obesity #oac #weightbias | Kailera ...
Kailera Therapeutics, an obesity drug startup, raises $600 million
Any insight on Kailera Therapeutics? Hey all! Do... | Fishbowl
Kailera | GLP-1 Therapies for Obesity Care | Life at Kailera
Kailera Therapeutics secures $600M Series B, advancing Hengrui-licensed ...
Kailera Therapeutics（KLRA）：肥満症および関連する心代謝系疾患を対象とする次世代治療薬の開発｜SecondWave ...
Kailera nets $600M more to advance Zepbound-like obesity drug ...
Kailera raises $600M in Series B, advances KAI-9531 into Phase III ...
Kailera jumps on weight-loss drug bandwagon with $400 mln early-stage ...
Kailera Therapeutics Launches Global Phase 3 Program for Ribupatide in ...
Kailera launches with $400M series A, 4 Chinese obesity drugs
BioCentury - Kailera seeks to differentiate GLP-1/GIP agonist after ...
Kailera Therapeutics Announces First Participants Randomized in ...
Kailera Therapeutics Announces $600 Million Series B Financing to ...
Investors raise $400 million for obesity startup Kailera Therapeutics
Kailera emerges with $400m to advance next-generation weight loss drugs
Kailera Therapeutics Raises $600 Million Series B to Advance Obesity ...
Kailera | GLP-1 Therapies for Obesity Care | Our Approach
Kailera Therapeutics $600M Series B for KAI-9531 Obesity Drug
Kailera raises hefty $600M to take Zepbound rival into ph. 3
Kailera Therapeutics Pursues IPO On Promising GLP-1 Trial Results (KLRA ...
恒瑞的NewCo公司Kailera计划在纳斯达克上市 近日， 恒瑞医药 GLP-1资产海外NewCo公司Kailera ...
kaillera(카일레라) 서버 실행하기 : 네이버 블로그
London Stock Exchange | London Stock Exchange
恒瑞医药GLP-1类新药“出海”：Kailera成立、B轮6亿融资与全球3期试验将启_摩熵医药
Novo Nordisk News | The Pharmaletter
#kaileaders #kaileaders #meetthemanager #kaicrew #kaileratx # ...
恒瑞的NewCo公司Kailera计划在纳斯达克上市医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
4亿美元A轮融资！潜在“best-in-class”减肥疗法即将进入3期临床_腾讯新闻
